- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04181879
Appropriate Polypharmacy in Older People in Primary Care (PolyPrime)
A Pilot Cluster Randomised Controlled Trial of a Theory-based Intervention to Improve Appropriate Polypharmacy in Older People in Primary Care
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Design: We will perform a pilot cluster randomised controlled trial where 12 GP practices will be randomly assigned (6 GP practices per arm) to the intervention group versus usual care. Randomisation will be stratified according to location (Northern Ireland /Republic of Ireland - Cavan, Donegal, Leitrim, Louth, Monaghan and Sligo). GP practices will be randomly allocated to the intervention or usual care arm after patient screening and recruitment. A total of 120 patients (60 per study arm, approximately 10 patients, randomly selected, per GP practice) will be enrolled into the study.
Design: Pilot cluster randomized controlled trial
Unit of randomization: GP practice.
Unit of analysis: Patient and GP practice.
Setting: Practices located in Northern Ireland will be recruited via Research Nurse(s) from the Northern Ireland Clinical Research Network (NICRN - Primary Care). In the Republic of Ireland a Research Nurse(s) from Trinity College Dublin will recruit GP practices located in the border counties of Cavan, Donegal, Leitrim, Louth, Monaghan and Sligo.
Study aim: The overall aim of the study is to undertake a pilot cluster randomised controlled trial (cRCT) of a theory-based intervention targeting prescribing of appropriate polypharmacy in primary care (PolyPrime) to assess the feasibility of a definitive cRCT of the PolyPrime intervention.
The main study objectives are:
- To test approaches to sampling, recruitment and retention of GP practices
- To test approaches to screening, recruitment and retention of patients
- To test the feasibility of using medication appropriateness (assessed using the STOPP/START criteria) as the primary outcome in a future cRCT
- To identify the intervention's likely mechanism of action
- To assess if the intervention was delivered and received as intended (intervention fidelity)
- To identify the resources used in the set-up and delivery of the intervention and their associated costs
- To assess the feasibility of a future cost-effectiveness analysis
- To further validate the Medication-Related Burden quality of life (MRQ-QoL) tool
- To obtain estimates of effect size between groups, cluster size and intraclass correlation coefficients (ICCs) to inform the sample size calculation for a full RCT
Recruitment strategy for patients: Each recruited general practice will be asked to recruit 10 older patients meeting the inclusion criteria (i.e. over 70 years old, receiving four or more regular medicines, not cognitively impaired, not have a terminal illness, resident in the community, be in receipt of a valid general medical services (GMS) card in the Republic of Ireland, or for Northern Ireland patients, registered for NHS primary care services and registered with and/or regularly attending the practice for a minimum of 12 months). Each recruited GP practice will also display a patient recruitment poster in their practice waiting areas. Posters will direct patients to ask at reception if they are interested in taking part in the study.
The GP Practice Manager (or equivalent) will screen patient records facilitated and supported by the research nurses. Each practice will identify and filter potentially eligible participants via patient records. This will be done in batches depending upon the size of the practice list. Patients will be screened on the basis of the inclusion/exclusion criteria as specified in the protocol. A screening log will be provided to practices to record screening and recruitment activity, including the reason(s) for not being enrolled on the study. The screening log will be kept securely at the practice and no identifying data will leave the practice.
Intervention delivery: The intervention (video) will be delivered to recruited GPs allocated to the intervention arm using the 'Riverside' software programme. This software programme allows electronic, multimedia material to be delivered to healthcare professionals and students. GPs will be provided with a single generic username and password that will allow them to access the video on a secure online server. Prior to the commencement of the study, all participating GPs will be provided with instructions from the researcher on how to access the video. The researcher will be fully contactable during the study to answer any questions or queries that participating GPs may have about accessing the video.
Once consented, patients recruited by the GP practices allocated to the intervention arm will be asked to attend two appointments (telephone or online consultations where a face-to-face consultation is not possible) at a time convenient to them to have their medicines reviewed by a GP in addition to their usual care. Patients recruited by the GP practices allocated to the control arm will continue to receive usual care.
Data will be collected from recruited GPs, recruited patients and practice records. Recruited patients will be asked to complete a number of questionnaires relating to their general well-being and use of the health service (e.g. hospital admissions) at baseline, six months and nine months post-initial medication review in the intervention arm and the equivalent time points in the control arm. The follow up time points for the control arm will be based on the average length of time from the completion of baseline data collection to six and nine months post initial medication review in the intervention arm. Patient data (including medical history, clinical conditions, biochemical data (i.e. test results) and prescribed medications) will also be collected from GP records at baseline, six months and nine months by a Research Nurse from the Northern Ireland Clinical Research Network (NICRN Primary Care) or Trinity College Dublin (TCD).
At the end of the intervention, interviews will be conducted with up to 10 GPs and six members of practice staff (i.e. those involved in implementing the intervention within each practice) respectively in the six intervention arm practices. GPs will be asked about their views on the support provided by the research team; the intervention package (and supporting materials); study procedures (e.g. screening, recruitment, etc.), while practice staff will be asked about their views on the study procedures (e.g. screening, recruitment, etc.) and acceptability of the intervention. Patients from the six intervention group practices will be asked to complete a feedback questionnaire after the delivery of the intervention (i.e. after completion of their final follow-up questionnaires). Patients will be asked about their views on the study procedures (e.g. completing questionnaires, recruitment etc.) and acceptability of the intervention.
Who is funding the study: HSC R&D Division Cross-border Healthcare Intervention Trials in Ireland Network (CHITIN), UK and Ireland
Study Type
Enrollment (Actual)
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
-
Dublin, Ireland, D02PN40
- Trinity College Dublin
-
-
-
-
Antrim
-
Belfast, Antrim, United Kingdom, BT9 7BL
- Queen's University Belfast
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Patients must be ≥70 years
- Patients must be receiving four or more regular medicines
- Patients must be resident in the community
- Patients must be in receipt of a valid general medical services (GMS) card in the Republic of Ireland, or in the case of Northern Ireland patients, registered for NHS primary care services
- Patients must be registered with and/or regularly attending the practice for a minimum of 12 months
Exclusion Criteria:
- Care home residents
- Patients who are cognitively impaired
- Patients with a terminal illness
- Involved in other Investigational Medicinal Product (IMP) or medicines management studies
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Health Services Research
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Single
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
|---|---|
|
Experimental: Intervention
GPs will receive the intervention package and conduct medication reviews with recruited patients
|
Other Names:
|
|
No Intervention: Usual care
GPs will continue to treat recruited patients as usual
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
The number of patients contacted and recruited
Time Frame: Through study completion, an average of 1 year
|
Through study completion, an average of 1 year
|
|
|
The number of GP practices contacted and recruited
Time Frame: Through study completion, an average of 1 year
|
Through study completion, an average of 1 year
|
|
|
The retention rate of patients
Time Frame: Through study completion, an average of 1 year
|
The number of patients retained over the study period
|
Through study completion, an average of 1 year
|
|
The retention rate of GP practices
Time Frame: Through study completion, an average of 1 year
|
The number of GP practices retained over the study period
|
Through study completion, an average of 1 year
|
|
Medication appropriateness
Time Frame: Baseline
|
Assessed using STOPP/START criteria
|
Baseline
|
|
Medication appropriateness
Time Frame: Six months' post-initial medication review in the intervention arm and the equivalent time points in the control arm
|
Assessed using STOPP/START criteria
|
Six months' post-initial medication review in the intervention arm and the equivalent time points in the control arm
|
|
Medication appropriateness
Time Frame: Nine months' post-initial medication review in the intervention arm and the equivalent time points in the control arm
|
Assessed using STOPP/START criteria
|
Nine months' post-initial medication review in the intervention arm and the equivalent time points in the control arm
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
The number of video view counts per GP participant for the online video
Time Frame: Through study completion, an average of 1 year
|
The number of times the GPs watched the online video; taken from the hosting website
|
Through study completion, an average of 1 year
|
|
The numbers of appointments scheduled
Time Frame: Through study completion, an average of 1 year
|
Collected on study-specific data collection forms
|
Through study completion, an average of 1 year
|
|
The number of medication review appointments attended (first and second reviews)
Time Frame: Through study completion, an average of 1 year
|
Collected on study-specific data collection forms
|
Through study completion, an average of 1 year
|
|
The length of the medication reviews
Time Frame: Through study completion, an average of 1 year
|
The length of the medication reviews will be based on audio-recordings of a selection of patient medication reviews
|
Through study completion, an average of 1 year
|
|
The number of scheduled weekly meetings within each practice at which explicit plans were made to recall patients for medication reviews
Time Frame: Through study completion, an average of 1 year
|
Recorded on GP practice staff data collection form
|
Through study completion, an average of 1 year
|
|
The number of prompts made by reception staff
Time Frame: Through study completion, an average of 1 year
|
The number of prompts made by reception staff will be recorded on a GP practice staff data collection form
|
Through study completion, an average of 1 year
|
|
The resource use and associated costs of the intervention
Time Frame: Baseline, six months' post-initial medication review in the intervention arm and the equivalent time points in the control arm and nine months' post-initial medication review in the intervention arm and the equivalent time points in the control arm
|
Baseline, six months' post-initial medication review in the intervention arm and the equivalent time points in the control arm and nine months' post-initial medication review in the intervention arm and the equivalent time points in the control arm
|
|
|
Participant health and social care service use
Time Frame: Baseline, six months' post-initial medication review in the intervention arm and the equivalent time points in the control arm and 12 months' post--initial medication review in the intervention arm and the equivalent time points in the control arm
|
As reported in GP notes and compared with self-reported health service use
|
Baseline, six months' post-initial medication review in the intervention arm and the equivalent time points in the control arm and 12 months' post--initial medication review in the intervention arm and the equivalent time points in the control arm
|
|
Health-related quality of life
Time Frame: Baseline, six months' post-initial medication review in the intervention arm and the equivalent time points in the control arm and nine months' post-initial medication review in the intervention arm and the equivalent time points in the control arm
|
Measured using the EQ-5D-5L
|
Baseline, six months' post-initial medication review in the intervention arm and the equivalent time points in the control arm and nine months' post-initial medication review in the intervention arm and the equivalent time points in the control arm
|
|
Medication-Related Burden Quality of Life
Time Frame: Baseline, six months' post-initial medication review in the intervention arm and the equivalent time points in the control arm and nine months' post-initial medication review in the intervention arm and the equivalent time points in the control arm
|
Measured using the Medication-Related Burden Quality of Life (MRB-QoL) tool
|
Baseline, six months' post-initial medication review in the intervention arm and the equivalent time points in the control arm and nine months' post-initial medication review in the intervention arm and the equivalent time points in the control arm
|
|
Estimates of effect size between groups, cluster size and intraclass correlation coefficients (ICCs)
Time Frame: Through study completion, an average of 1 year
|
Through study completion, an average of 1 year
|
Collaborators and Investigators
Sponsor
Collaborators
Investigators
- Principal Investigator: Carmel Hughes, PhD, Queen's University, Belfast
Publications and helpful links
General Publications
- Cadogan CA, Ryan C, Gormley GJ, Francis JJ, Passmore P, Kerse N, Hughes CM. A feasibility study of a theory-based intervention to improve appropriate polypharmacy for older people in primary care. Pilot Feasibility Stud. 2017 Jul 20;4:23. doi: 10.1186/s40814-017-0166-3. eCollection 2018. Erratum In: Pilot Feasibility Stud. 2017 Oct 24;3:48.
- Cadogan CA, Ryan C, Francis JJ, Gormley GJ, Passmore P, Kerse N, Hughes CM. Development of an intervention to improve appropriate polypharmacy in older people in primary care using a theory-based method. BMC Health Serv Res. 2016 Nov 16;16(1):661. doi: 10.1186/s12913-016-1907-3.
- Rankin A, Cadogan CA, Barry HE, Gardner E, Agus A, Molloy GJ, Gorman A, Ryan C, Leathem C, Maxwell M, Gormley GJ, Ferrett A, McCarthy P, Fahey T, Hughes CM; PolyPrime team. An external pilot cluster randomised controlled trial of a theory-based intervention to improve appropriate polypharmacy in older people in primary care (PolyPrime): study protocol. Pilot Feasibility Stud. 2021 Mar 19;7(1):77. doi: 10.1186/s40814-021-00822-2.
- Rankin A, Molloy GJ, Cadogan CA, Barry HE, Gorman A, Ryan C, Ferrett A, McCarthy P, Gormley GJ, Fahey T, Hughes CM; PolyPrime team. Protocol for a process evaluation of an external pilot cluster randomised controlled trial of a theory-based intervention to improve appropriate polypharmacy in older people in primary care: the PolyPrime study. Trials. 2021 Jul 14;22(1):449. doi: 10.1186/s13063-021-05410-6.
- Rankin A, Gorman A, Cole J, Cadogan CA, Barry HE, Agus A, Logan D, McDowell C, Molloy GJ, Ryan C, Leathem C, Maxwell M, Brennan C, Gormley GJ, Ferrett A, McCarthy P, Fahey T, Hughes CM; PolyPrime team. An external pilot cluster randomised controlled trial of a theory-based intervention to improve appropriate polypharmacy in older people in primary care (PolyPrime). Pilot Feasibility Stud. 2022 Sep 10;8(1):203. doi: 10.1186/s40814-022-01161-6.
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Anticipated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Other Study ID Numbers
- B19/20
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
IPD Plan Description
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
product manufactured in and exported from the U.S.
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Polypharmacy
-
Pharmacie des Hopitaux de l'Est LemaniqueRecruiting
-
University of RochesterNational Institute on Aging (NIA)CompletedPolypharmacyUnited States
-
Universitaire Ziekenhuizen KU LeuvenWithdrawn
-
Tabula Rasa HealthCareEnrolling by invitationPolypharmacy | PharmacogenomicsUnited States
-
University of BernUniversity of Zurich; Swiss National Science Foundation; University of Basel; Utrecht...CompletedMultimorbidity | PolypharmacySwitzerland
-
Royal College of Surgeons, IrelandUniversity of Dublin, Trinity College; Health Service Executive, IrelandCompletedMultimorbidity | PolypharmacyIreland
-
Université Catholique de LouvainActive, not recruitingMedication Review | Polypharmacy (People Under Treatment With 5 or More Drugs) | Polypharmacy, Decision-makingBelgium
-
Radboud University Medical CenterUniversity Medical Center Groningen; UMC Utrecht; Erasmus Medical Center; Catharina... and other collaboratorsActive, not recruitingPolypharmacy | Medication ReviewNetherlands
-
Anne NiquilleCompletedPolypharmacy | Inappropriate PrescribingSwitzerland
-
Leiden University Medical CenterRWTH Aachen University; University of Patras; University of LjubljanaRecruitingPolypharmacyGermany, Greece, Slovenia
Clinical Trials on Intervention
-
Biolux Research Holdings, Inc.TerminatedOrthodontic Tooth MovementCanada
-
Nottingham Trent UniversityUnknownOverweight and ObesityUnited Kingdom
-
University of California, San FranciscoNational Cancer Institute (NCI)CompletedColorectal Carcinoma | Healthy Subject | Health Status UnknownUnited States
-
University of Southern DenmarkTrygFonden, DenmarkUnknownObesity | Overweight | Metabolic Syndrome | ChildrenDenmark
-
University of FloridaCompletedSensitivityUnited States
-
Ohio State University Comprehensive Cancer CenterCompleted
-
Mayo ClinicNational Cancer Institute (NCI)WithdrawnCancer Survivor | Peripheral Sensory Neuropathy
-
Roswell Park Cancer InstituteNational Cancer Institute (NCI)CompletedStage 0a Bladder Cancer AJCC v8 | Stage 0is Bladder Cancer AJCC v8 | Stage I Bladder Cancer AJCC v8United States
-
Universidad de ExtremaduraDiputación Provincial de BadajozRecruitingHealth Education | Gamification in Health EducationSpain
-
Jordi Gol i Gurina FoundationInstituto de Salud Carlos IIINot yet recruiting